Photo by atikahakhtar from unsplash
Dear Editor, Secukinumab, a monoclonal antibody against interleukin (IL)-17A, is used to treat psoriasis and psoriatic arthritis. The effect of this treatment on COVID-19 vaccination is not well characterized. While… Click to show full abstract
Dear Editor, Secukinumab, a monoclonal antibody against interleukin (IL)-17A, is used to treat psoriasis and psoriatic arthritis. The effect of this treatment on COVID-19 vaccination is not well characterized. While IL-17 deficiency states are associated with mucocutaneous infection with Candida albicans, there is no apparent increased risk of viral infection, and redundancy between IL-17A and IL-17F limits the impact of IL-17A deficiency on immune responsiveness.
Keywords:
dermatology;
vaccination efficacy;
treatment;
secukinumab treatment;
treatment vaccination;
vaccination
Journal Title: Clinical and experimental dermatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical and experimental dermatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!